Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Chromosomal alterations in exfoliated urothelial cells from bladder cancer cases and healthy men: a prospective screening study

Authors: Nadine Bonberg, Beate Pesch, Thomas Behrens, Georg Johnen, Dirk Taeger, Katarzyna Gawrych, Christian Schwentner, Harald Wellhäußer, Matthias Kluckert, Gabriele Leng, Michael Nasterlack, Christoph Oberlinner, Arnulf Stenzl, Thomas Brüning

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Chromosomal instability in exfoliated urothelial cells has been associated with the development of bladder cancer. Here, we analyzed the accumulation of copy number variations (CNVs) using fluorescence in situ hybridization in cancer cases and explored factors associated with the detection of CNVs in tumor-free men.

Methods

The prospective UroScreen study was designed to investigate the performance of UroVysion™ and other tumor tests for the early detection of bladder cancer in chemical workers from 2003–2010. We analyzed a database compiling CNVs of chromosomes 3, 7, and 17 and at 9p21 that were detected in 191,434 exfoliated urothelial cells from 1,595 men. We assessed the accumulation of CNVs in 1,400 cells isolated from serial samples that were collected from 18 cancer cases up to the time of diagnosis. A generalized estimating equation model was applied to evaluate the influence of age, smoking, and urine status on CNVs in cells from tumor-free men.

Results

Tetrasomy of chromosomes 3, 7 and 17, and DNA loss at 9p21 were the most frequently observed forms of CNV. In bladder cancer cases, we observed an accumulation of CNVs that started approximately three years before diagnosis. During the year prior to diagnosis, cells from men with high-grade bladder cancer accumulated more CNVs than those obtained from cases with low-grade cancer (CNV < 2: 7.5% vs. 1.1%, CNV > 2: 16-17% vs. 9-11%). About 1% of cells from tumor-free men showed polysomy of chromosomes 3, 7, or 17 or DNA loss at 9p21. Men aged ≥50 years had 1.3-fold more cells with CNVs than younger men; however, we observed no further age-related accumulation of CNVs in tumor-free men. Significantly more cells with CNVs were detected in samples with low creatinine concentrations.

Conclusions

We found an accumulation of CNVs during the development of bladder cancer starting three years before diagnosis, with more altered cells identified in high-grade tumors. Also, a small fraction of cells with CNVs were exfoliated into urine of tumor-free men, mainly exhibiting tetraploidy or DNA loss at 9p21. Whether these cells are preferentially cleared from the urothelium or are artifacts needs further exploration.
Literature
1.
go back to reference Florl AR, Schulz WA: Chromosomal instability in bladder cancer. Arch Toxicol. 2008, 82 (3): 173-182. 10.1007/s00204-008-0280-3.CrossRefPubMed Florl AR, Schulz WA: Chromosomal instability in bladder cancer. Arch Toxicol. 2008, 82 (3): 173-182. 10.1007/s00204-008-0280-3.CrossRefPubMed
2.
go back to reference Lauss M, Aine M, Sjödahl G, Veerla S, Patschan O, Gudjonsson S, Chebil G, Lövgren K, Fernö M, Månsson W, Liedberg F, Ringnér M, Lindgren D, Höglund M: DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Epigenetics. 2012, 7 (8): 858-867. 10.4161/epi.20837.CrossRefPubMedPubMedCentral Lauss M, Aine M, Sjödahl G, Veerla S, Patschan O, Gudjonsson S, Chebil G, Lövgren K, Fernö M, Månsson W, Liedberg F, Ringnér M, Lindgren D, Höglund M: DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Epigenetics. 2012, 7 (8): 858-867. 10.4161/epi.20837.CrossRefPubMedPubMedCentral
3.
go back to reference Duesberg P, Li R: Multistep carcinogenesis: a chain reaction of aneuploidizations. Cell Cycle. 2003, 2 (3): 202-210.CrossRefPubMed Duesberg P, Li R: Multistep carcinogenesis: a chain reaction of aneuploidizations. Cell Cycle. 2003, 2 (3): 202-210.CrossRefPubMed
4.
go back to reference Ricke RM, van Ree JH, van Deursen JM: Whole chromosome instability and cancer: a complex relationship. Trends Genet. 2008, 24 (9): 457-466. 10.1016/j.tig.2008.07.002.CrossRefPubMedPubMedCentral Ricke RM, van Ree JH, van Deursen JM: Whole chromosome instability and cancer: a complex relationship. Trends Genet. 2008, 24 (9): 457-466. 10.1016/j.tig.2008.07.002.CrossRefPubMedPubMedCentral
5.
go back to reference Lv L, Zhang T, Yi Q, Huang Y, Wang Z, Hou H, Zhang H, Zheng W, Hao Q, Guo Z, Cooke HJ, Shi Q: Tetraploid cells from cytokinesis failure induce aneuploidy and spontaneous transformation of mouse ovarian surface epithelial cells. Cell Cycle. 2012, 11 (15): 2864-2875. 10.4161/cc.21196.CrossRefPubMedPubMedCentral Lv L, Zhang T, Yi Q, Huang Y, Wang Z, Hou H, Zhang H, Zheng W, Hao Q, Guo Z, Cooke HJ, Shi Q: Tetraploid cells from cytokinesis failure induce aneuploidy and spontaneous transformation of mouse ovarian surface epithelial cells. Cell Cycle. 2012, 11 (15): 2864-2875. 10.4161/cc.21196.CrossRefPubMedPubMedCentral
6.
go back to reference Duesberg P, Li R, Fabarius A, Hehlmann R: Aneuploidy and cancer: from correlation to causation. Contrib Microbiol. 2006, 13: 16-44.CrossRefPubMed Duesberg P, Li R, Fabarius A, Hehlmann R: Aneuploidy and cancer: from correlation to causation. Contrib Microbiol. 2006, 13: 16-44.CrossRefPubMed
7.
go back to reference Vitale I, Galluzzi L, Castedo M, Kroemer G: Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011, 12 (6): 385-392. 10.1038/nrm3115.CrossRefPubMed Vitale I, Galluzzi L, Castedo M, Kroemer G: Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011, 12 (6): 385-392. 10.1038/nrm3115.CrossRefPubMed
8.
9.
11.
go back to reference Vijg J, Suh Y: Genome instability and aging. Annu Rev Physiol. 2013, 75: 645-668. 10.1146/annurev-physiol-030212-183715.CrossRefPubMed Vijg J, Suh Y: Genome instability and aging. Annu Rev Physiol. 2013, 75: 645-668. 10.1146/annurev-physiol-030212-183715.CrossRefPubMed
12.
go back to reference Fenech M, Holland N, Zeiger E, Chang WP, Burgaz S, Thomas P, Bolognesi C, Knasmueller S, Kirsch-Volders M, Bonassi S: The HUMN and HUMNxL international collaboration projects on human micronucleus assays in lymphocytes and buccal cells–past, present and future. Mutagenesis. 2011, 26 (1): 239-245. 10.1093/mutage/geq051.CrossRefPubMed Fenech M, Holland N, Zeiger E, Chang WP, Burgaz S, Thomas P, Bolognesi C, Knasmueller S, Kirsch-Volders M, Bonassi S: The HUMN and HUMNxL international collaboration projects on human micronucleus assays in lymphocytes and buccal cells–past, present and future. Mutagenesis. 2011, 26 (1): 239-245. 10.1093/mutage/geq051.CrossRefPubMed
13.
go back to reference Gabriel U, Giehl M, Haass W, Trojan L, Michel MS, Hofmann WK, Seifarth W, Fabarius A: Urine from current smokers induces centrosome aberrations and spindle defects in vitro in nonmalignant human cell lines. Cancer Genet Cytogenet. 2010, 203 (2): 253-262. 10.1016/j.cancergencyto.2010.07.135.CrossRefPubMed Gabriel U, Giehl M, Haass W, Trojan L, Michel MS, Hofmann WK, Seifarth W, Fabarius A: Urine from current smokers induces centrosome aberrations and spindle defects in vitro in nonmalignant human cell lines. Cancer Genet Cytogenet. 2010, 203 (2): 253-262. 10.1016/j.cancergencyto.2010.07.135.CrossRefPubMed
14.
go back to reference Lenz P, Pfeiffer R, Baris D, Schned AR, Takikita M, Poscablo MC, Schwenn M, Johnson A, Jones M, Kida M, Cantor KP, Rothman N, Silverman DT, Hewitt SM, Moore LE: Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont. Cancer Epidemiol Biomarkers Prev. 2012, 21 (9): 1555-1564. 10.1158/1055-9965.EPI-12-0261.CrossRefPubMedPubMedCentral Lenz P, Pfeiffer R, Baris D, Schned AR, Takikita M, Poscablo MC, Schwenn M, Johnson A, Jones M, Kida M, Cantor KP, Rothman N, Silverman DT, Hewitt SM, Moore LE: Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont. Cancer Epidemiol Biomarkers Prev. 2012, 21 (9): 1555-1564. 10.1158/1055-9965.EPI-12-0261.CrossRefPubMedPubMedCentral
15.
go back to reference Furney SJ, Gundem G, Lopez-Bigas N: Oncogenomics methods and resources. Cold Spring Harb Protoc. 2012, 2012 (5): 546-564.CrossRef Furney SJ, Gundem G, Lopez-Bigas N: Oncogenomics methods and resources. Cold Spring Harb Protoc. 2012, 2012 (5): 546-564.CrossRef
17.
go back to reference Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB: Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2005, 66 (6 Suppl 1): 64-74.CrossRefPubMed Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB: Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2005, 66 (6 Suppl 1): 64-74.CrossRefPubMed
18.
go back to reference Banek S, Schwentner C, Täger D, Pesch B, Nasterlack M, Leng G, Gawrych K, Bonberg N, Johnen G, Kluckert M, Gakis G, Todenhöfer T, Hennenlotter J, Brüning T, Stenzl A, UroScreen Study Group: Prospective evaluation of fluorescence-in-situ-hybridization to detect bladder cancer: Results from the UroScreen-study. Urol Oncol. doi:101016/jurolonc 2012 04 015 2012 Banek S, Schwentner C, Täger D, Pesch B, Nasterlack M, Leng G, Gawrych K, Bonberg N, Johnen G, Kluckert M, Gakis G, Todenhöfer T, Hennenlotter J, Brüning T, Stenzl A, UroScreen Study Group: Prospective evaluation of fluorescence-in-situ-hybridization to detect bladder cancer: Results from the UroScreen-study. Urol Oncol. doi:101016/jurolonc 2012 04 015 2012
19.
go back to reference Bonberg N, Taeger D, Gawrych K, Johnen G, Banek S, Schwentner C, Sievert KD, Wellhäußer H, Kluckert M, Leng G, Nasterlack M, Stenzl A, Behrens T, Brüning T, Pesch B, UroScreen Study Group: Chromosomal instability and bladder cancer - the UroVysion™ test in the UroScreen study. BJU Int. doi:101111/j1464-410X201211666x2013 Bonberg N, Taeger D, Gawrych K, Johnen G, Banek S, Schwentner C, Sievert KD, Wellhäußer H, Kluckert M, Leng G, Nasterlack M, Stenzl A, Behrens T, Brüning T, Pesch B, UroScreen Study Group: Chromosomal instability and bladder cancer - the UroVysion™ test in the UroScreen study. BJU Int. doi:101111/j1464-410X201211666x2013
20.
go back to reference Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N, Pelster M, Johnen G, Bontrup H, Wellhäusser H, Bierfreund HG, Wiens C, Bayer C, Eberle F, Scheuermann B, Kluckert M, Feil G, Brüning T, Stenzl A, UroScreen Study Group: Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer: results from the UroScreen study. BJU Int. 2012, 110: 699-708. 10.1111/j.1464-410X.2011.10883.x.CrossRefPubMed Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N, Pelster M, Johnen G, Bontrup H, Wellhäusser H, Bierfreund HG, Wiens C, Bayer C, Eberle F, Scheuermann B, Kluckert M, Feil G, Brüning T, Stenzl A, UroScreen Study Group: Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer: results from the UroScreen study. BJU Int. 2012, 110: 699-708. 10.1111/j.1464-410X.2011.10883.x.CrossRefPubMed
21.
go back to reference Johnen G, Gawrych K, Bontrup H, Pesch B, Taeger D, Banek S, Kluckert M, Wellhäußer H, Eberle F, Nasterlack M, Leng G, Stenzl A, Brüning T, UroScreen Study Group: Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen. PLoS One. 2012, 7 (4): e35363-10.1371/journal.pone.0035363.CrossRefPubMedPubMedCentral Johnen G, Gawrych K, Bontrup H, Pesch B, Taeger D, Banek S, Kluckert M, Wellhäußer H, Eberle F, Nasterlack M, Leng G, Stenzl A, Brüning T, UroScreen Study Group: Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen. PLoS One. 2012, 7 (4): e35363-10.1371/journal.pone.0035363.CrossRefPubMedPubMedCentral
22.
go back to reference Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, Feil G, Johnen G, Ickstadt K, Kluckert M, Wellhäusser H, Stenzl A, Brüning T, UroScreen Group: The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int. 2011, 108 (4): 546-552. 10.1111/j.1464-410X.2010.09971.x.CrossRefPubMed Pesch B, Nasterlack M, Eberle F, Bonberg N, Taeger D, Leng G, Feil G, Johnen G, Ickstadt K, Kluckert M, Wellhäusser H, Stenzl A, Brüning T, UroScreen Group: The role of haematuria in bladder cancer screening among men with former occupational exposure to aromatic amines. BJU Int. 2011, 108 (4): 546-552. 10.1111/j.1464-410X.2010.09971.x.CrossRefPubMed
23.
go back to reference Pesch B, Taeger D, Johnen G, Gawrych K, Bonberg N, Schwentner C, Wellhäusser H, Kluckert M, Leng G, Nasterlack M, Lotan Y, Stenzl A, Brüning T, UroScreen Study Group: Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. Int Arch Occup Environ Health. 2013, 87 (7): 715-724.CrossRefPubMed Pesch B, Taeger D, Johnen G, Gawrych K, Bonberg N, Schwentner C, Wellhäusser H, Kluckert M, Leng G, Nasterlack M, Lotan Y, Stenzl A, Brüning T, UroScreen Study Group: Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. Int Arch Occup Environ Health. 2013, 87 (7): 715-724.CrossRefPubMed
24.
go back to reference Zeger SL, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986, 42 (1): 121-130. 10.2307/2531248.CrossRefPubMed Zeger SL, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986, 42 (1): 121-130. 10.2307/2531248.CrossRefPubMed
25.
go back to reference Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100 (1): 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100 (1): 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
26.
go back to reference Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144 (5): 646-674. 10.1016/j.cell.2011.02.013.CrossRefPubMed Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144 (5): 646-674. 10.1016/j.cell.2011.02.013.CrossRefPubMed
27.
go back to reference Rajagopalan H, Lengauer C: Aneuploidy and cancer. Nature. 2004, 432 (7015): 338-341. 10.1038/nature03099.CrossRefPubMed Rajagopalan H, Lengauer C: Aneuploidy and cancer. Nature. 2004, 432 (7015): 338-341. 10.1038/nature03099.CrossRefPubMed
28.
go back to reference Brenner DE, Normolle DP: Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum. Cancer Epidemiol Biomarkers Prev. 2007, 16 (10): 1918-1920. 10.1158/1055-9965.EPI-07-2619.CrossRefPubMed Brenner DE, Normolle DP: Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum. Cancer Epidemiol Biomarkers Prev. 2007, 16 (10): 1918-1920. 10.1158/1055-9965.EPI-07-2619.CrossRefPubMed
29.
go back to reference Pesch B, Brüning T, Johnen G, Casjens S, Bonberg N, Taeger D, Müller A, Weber DG, Behrens T: Biomarker research with prospective study designs for the early detection of cancer. Biochim Biophys Acta. 2014, 1844 (5): 874-883. 10.1016/j.bbapap.2013.12.007.CrossRefPubMed Pesch B, Brüning T, Johnen G, Casjens S, Bonberg N, Taeger D, Müller A, Weber DG, Behrens T: Biomarker research with prospective study designs for the early detection of cancer. Biochim Biophys Acta. 2014, 1844 (5): 874-883. 10.1016/j.bbapap.2013.12.007.CrossRefPubMed
30.
go back to reference Lotan Y, Shariat SF, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stöhr B, Bassi PF, Grossman HB: Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol. 2010, 28 (4): 441-448. 10.1016/j.urolonc.2009.11.004.CrossRefPubMed Lotan Y, Shariat SF, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stöhr B, Bassi PF, Grossman HB: Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol. 2010, 28 (4): 441-448. 10.1016/j.urolonc.2009.11.004.CrossRefPubMed
31.
go back to reference Vitale I, Galluzzi L, Senovilla L, Criollo A, Jemaà M, Castedo M, Kroemer G: Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death Differ. 2011, 18 (9): 1403-1413. 10.1038/cdd.2010.145.CrossRefPubMed Vitale I, Galluzzi L, Senovilla L, Criollo A, Jemaà M, Castedo M, Kroemer G: Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death Differ. 2011, 18 (9): 1403-1413. 10.1038/cdd.2010.145.CrossRefPubMed
32.
go back to reference Cimini D, Degrassi F: Aneuploidy: a matter of bad connections. Trends Cell Biol. 2005, 15 (8): 442-451. 10.1016/j.tcb.2005.06.008.CrossRefPubMed Cimini D, Degrassi F: Aneuploidy: a matter of bad connections. Trends Cell Biol. 2005, 15 (8): 442-451. 10.1016/j.tcb.2005.06.008.CrossRefPubMed
33.
go back to reference Kibel AS, Faith DA, Bova GS, Isaacs WB: Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. J Urol. 2000, 164 (1): 192-196. 10.1016/S0022-5347(05)67493-9.CrossRefPubMed Kibel AS, Faith DA, Bova GS, Isaacs WB: Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. J Urol. 2000, 164 (1): 192-196. 10.1016/S0022-5347(05)67493-9.CrossRefPubMed
34.
go back to reference Czarnecka KH, Migdalska-Sęk M, Antczak A, Pastuszak-Lewandoska D, Kordiak J, Nawrot E, Domańska D, Kaleta D, Górski P, Brzeziańska EB: Allelic imbalance in 1p, 7q, 9p, 11p, 12q and 16q regions in non-small cell lung carcinoma and its clinical association: a pilot study. Mol Biol Rep. 2013, 40 (12): 6671-6684. 10.1007/s11033-013-2782-1.CrossRefPubMedPubMedCentral Czarnecka KH, Migdalska-Sęk M, Antczak A, Pastuszak-Lewandoska D, Kordiak J, Nawrot E, Domańska D, Kaleta D, Górski P, Brzeziańska EB: Allelic imbalance in 1p, 7q, 9p, 11p, 12q and 16q regions in non-small cell lung carcinoma and its clinical association: a pilot study. Mol Biol Rep. 2013, 40 (12): 6671-6684. 10.1007/s11033-013-2782-1.CrossRefPubMedPubMedCentral
35.
go back to reference Chin L, Garraway LA, Fisher DE: Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006, 20 (16): 2149-2182. 10.1101/gad.1437206.CrossRefPubMed Chin L, Garraway LA, Fisher DE: Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 2006, 20 (16): 2149-2182. 10.1101/gad.1437206.CrossRefPubMed
36.
go back to reference Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, Luthra R, Logothetis C, Von Eschenbach AC, Grossman HB, Benedict WF, Batsakis JG: Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene. 1999, 18 (5): 1185-1196. 10.1038/sj.onc.1202385.CrossRefPubMed Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, Luthra R, Logothetis C, Von Eschenbach AC, Grossman HB, Benedict WF, Batsakis JG: Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene. 1999, 18 (5): 1185-1196. 10.1038/sj.onc.1202385.CrossRefPubMed
37.
go back to reference Louhelainen J, Wijkstrom H, Hemminki K: Initiation-development modelling of allelic losses on chromosome 9 in multifocal bladder cancer. Eur J Cancer. 2000, 36 (11): 1441-1451. 10.1016/S0959-8049(00)00127-1.CrossRefPubMed Louhelainen J, Wijkstrom H, Hemminki K: Initiation-development modelling of allelic losses on chromosome 9 in multifocal bladder cancer. Eur J Cancer. 2000, 36 (11): 1441-1451. 10.1016/S0959-8049(00)00127-1.CrossRefPubMed
38.
go back to reference Köhler CU, Martin L, Bonberg N, Behrens T, Deix T, Braun K, Noldus J, Jöckel KH, Erbel R, Sommerer F, Tannapfel A, Harth V, Käfferlein HU, Brüning T: Automated quantification of FISH signals in urinary cells enables the assessment of chromosomal aberration patterns characteristic for bladder cancer. Biochem Biophys Res Commun. 2014, 448 (4): 467-472. 10.1016/j.bbrc.2014.04.137.CrossRefPubMed Köhler CU, Martin L, Bonberg N, Behrens T, Deix T, Braun K, Noldus J, Jöckel KH, Erbel R, Sommerer F, Tannapfel A, Harth V, Käfferlein HU, Brüning T: Automated quantification of FISH signals in urinary cells enables the assessment of chromosomal aberration patterns characteristic for bladder cancer. Biochem Biophys Res Commun. 2014, 448 (4): 467-472. 10.1016/j.bbrc.2014.04.137.CrossRefPubMed
39.
go back to reference Horst BA, Terrano D, Fang Y, Silvers DN, Busam KJ: 9p21 gene locus in Spitz nevi of older individuals: absence of cytogenetic and immunohistochemical findings associated with malignancy. Hum Pathol. 2013, 44 (12): 2822-2828. 10.1016/j.humpath.2013.07.034.CrossRefPubMed Horst BA, Terrano D, Fang Y, Silvers DN, Busam KJ: 9p21 gene locus in Spitz nevi of older individuals: absence of cytogenetic and immunohistochemical findings associated with malignancy. Hum Pathol. 2013, 44 (12): 2822-2828. 10.1016/j.humpath.2013.07.034.CrossRefPubMed
40.
go back to reference Muto S, Horie S, Takahashi S, Tomita K, Kitamura T: Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res. 2000, 60 (15): 4021-4025.PubMed Muto S, Horie S, Takahashi S, Tomita K, Kitamura T: Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res. 2000, 60 (15): 4021-4025.PubMed
41.
go back to reference Halling KC, Kipp BR: Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol. 2008, 15 (5): 279-286. 10.1097/PAP.0b013e3181832320.CrossRefPubMed Halling KC, Kipp BR: Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol. 2008, 15 (5): 279-286. 10.1097/PAP.0b013e3181832320.CrossRefPubMed
42.
go back to reference Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W: The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000, 2 (3): 116-123. 10.1016/S1525-1578(10)60625-3.CrossRefPubMedPubMedCentral Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W: The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000, 2 (3): 116-123. 10.1016/S1525-1578(10)60625-3.CrossRefPubMedPubMedCentral
43.
go back to reference Zhivotovsky B, Kroemer G: Apoptosis and genomic instability. Nat Rev Mol Cell Biol. 2004, 5 (9): 752-762. 10.1038/nrm1443.CrossRefPubMed Zhivotovsky B, Kroemer G: Apoptosis and genomic instability. Nat Rev Mol Cell Biol. 2004, 5 (9): 752-762. 10.1038/nrm1443.CrossRefPubMed
44.
go back to reference Baker DJ, Dawlaty MM, Wijshake T, Jeganathan KB, Malureanu L, van Ree JH, Crespo-Diaz R, Reyes S, Seaburg L, Shapiro V, Behfar A, Terzic A, van de Sluis B, Van Deursen JM: Increased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespan. Nat Cell Biol. 2013, 15 (1): 96-102.CrossRefPubMed Baker DJ, Dawlaty MM, Wijshake T, Jeganathan KB, Malureanu L, van Ree JH, Crespo-Diaz R, Reyes S, Seaburg L, Shapiro V, Behfar A, Terzic A, van de Sluis B, Van Deursen JM: Increased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespan. Nat Cell Biol. 2013, 15 (1): 96-102.CrossRefPubMed
45.
go back to reference Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC: Association between smoking and risk of bladder cancer among men and women. JAMA. 2011, 306 (7): 737-745. 10.1001/jama.2011.1142.CrossRefPubMedPubMedCentral Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC: Association between smoking and risk of bladder cancer among men and women. JAMA. 2011, 306 (7): 737-745. 10.1001/jama.2011.1142.CrossRefPubMedPubMedCentral
46.
go back to reference Gandhi NM, Morales A, Lamm DL: Bacillus Calmette-Guerin immunotherapy for genitourinary cancer. BJU Int. 2013, 112 (3): 288-297. 10.1111/j.1464-410X.2012.11754.x.CrossRefPubMed Gandhi NM, Morales A, Lamm DL: Bacillus Calmette-Guerin immunotherapy for genitourinary cancer. BJU Int. 2013, 112 (3): 288-297. 10.1111/j.1464-410X.2012.11754.x.CrossRefPubMed
Metadata
Title
Chromosomal alterations in exfoliated urothelial cells from bladder cancer cases and healthy men: a prospective screening study
Authors
Nadine Bonberg
Beate Pesch
Thomas Behrens
Georg Johnen
Dirk Taeger
Katarzyna Gawrych
Christian Schwentner
Harald Wellhäußer
Matthias Kluckert
Gabriele Leng
Michael Nasterlack
Christoph Oberlinner
Arnulf Stenzl
Thomas Brüning
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-854

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine